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cancer care and management From the point of view of 
radiotherapy all of the above are relevant and pertinent. The 
changing epidemiology, treatment patterns and improved 
survival rates all raise the importance of comprehensive 
approaches. Radiotherapy has not seen appropriate attention 
in terms of economic evaluation since a lot of attention lies 
with the medical, i.e. phamacological treatment. Contrary to 
the analyses on the innovative therapies and new lines of 
cancer drugs, radiotherapy does not attract that many health 
technology assessments. There are at least the following 
reasons why it should: The greater and rising use of 
radiotherapy treatments in cancer care.The high cost of 
initial investment and maintenance – the latter being equally 
important as the formerThe need for more flexibility in its 
availability and useThe inherent multi- and interdisciplinarity 
needed to successfully carry out the radiotherapeutic care 
For policy makers often the immediate needs and problems 
are more relevant than rather remote projections. 
Nevertheless, the need to plan is even more pertinent to the 
investments needed for radiotherapy than for other types of 
care. This makes it benefit better from the planning process 
but also raises the need to better balance the different 
therapeutic elements in cancer care when adopting and 
changing guidelines and patient pathways. Consequently, 
plans may better reflect the future need for investment and 
for the planning and development of human resources. In 
that sense and through its dependance on technology, 
radiotherapy should be even more interested in supporting 
and contributing to the idea of the national cancer plans. 
There have been recent challenges for many countries lately. 
Austerity measures have cut into health care budgets 
similarly as into other public expenditures. Careful 
epidemiological analyses that can evaluate the contribution 
of the different elements of care to patient survival and 
quality of life are extremely important and may very often 
offset the costs of complex treatments. Radiotherapy is a 
vital element of comprehensive cancer care. Given its needs 
for careful planning, equipment purchases and development 
of human resources in combination with a rising need for 
radiotherapy, there is a definite need for clear identification 
of radiotherapy in national cancer plans. Only through such 
transparency it is possible to secure all the conditions for 
further development of cancer radiotherapy. 
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Purpose or Objective: Several clinical studies investigated 
hypofractionation schedules with fractions ≥ 3 Gy in prostate 
cancer. Recovery from rectal radiation damage has been 
reported to depend on weekly dose rates, implying that 
acute rectal toxicity is regarded as little fractionation 
sensitive. A phase 3 randomized trial, with dose delivery of 
≈10 Gy/week in both arms, recently reported a significantly 
higher peak incidence of RTOG grade ≥2 gastrointestinal (GI) 
toxicity in the 3.4 Gy vs the 2 Gy fractions arm. Here, we 
further analyzed the acute proctitis symptoms of the two 
schedules with 3.4 Gy or 2Gy fractions delivered with image-
guided (IG)-IMRT, and compared it with the incidence of 
patients receiving 2 Gy fractions delivered with a 3D 
conformal technique (3DCRT). 
 
Material and Methods: We selected patients treated with IG-
IMRT (planning margins 5-8 mm) from a randomized trial for 
localized prostate cancer, with patients in the 
Hypofractionation arm (HF, n=303) receiving 3 fractions per 
week of 3.4 Gy with ≈48h intervals, during 6.5 weeks. 
Patients in the standard arm (SF, n=298) received 5 fractions 
of 2 Gy per week with ≈24h intervals, for 8 weeks. A third 
historical group (3DCRT) contained patients from a previous 
trial (n=522) treated with 2 Gy/fraction (7-8 weeks), planning 
margins of 10 mm, and a three-field 3D-conformal technique. 
Prospectively collected patient-reported symptoms were 
available for week 4 and week 6. Peak incidences (maximum 
week 4 & 6) were compared between the groups (chisquare 
test). 
 
Results: We found a significantly increased risk for acute 
rectal bleeding in the HF group (15.1% versus 7.6% for SF, 
Table 1, Figure 1), which implies a relative risk of 2.0. 
Increased risks for HF vs SF (p<0.05) were also found for 
mucus loss, loose stools, and increased stool frequency. 
Figure 1 shows the incidences for bleeding and mucus loss 
(with 1 SE). The increased risks for bleeding in the HF 
schedule were comparable with the observed risks in the 
historical 3DCRT cohort. Risks for other toxicities with HF 
were somewhat lower than for 3DCRT, with no significant 
differences except for stools ≥4 (HF 34.7% vs 3DCRT 42.9%, 
p=0.02). Incidence of diarrhea exceeded that of the 3DCRT 
schedule, but not significantly (p=0.1). 
 
Conclusion: We observed significantly more acute proctitis 
symptoms in the HF group. These data might point to an 
underestimated fractionation sensitivity of acute rectal 
tissue. Our findings suggest that the repair capacity between 
two fractions was less effective when 3.4 Gy was delivered 
every other day, compared to daily 2 Gy fractions. The 
increased damage by hypofractionation is in the same order 
as the reduction in damage previously achieved with the  
introduction of IG-IMRT. 
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Purpose or Objective: IGRT enables accurate target volume 
localisation, potentially permitting reduced treatment 
margins, which may decrease normal tissue toxicity.  
Erectile dysfunction is a common toxicity of prostate RT and 
the penile bulb (PB) is suggested as a surrogate for 
undetermined structures critical for erectile function. 
However, PB dose-volume effects are not well established.  
We aim to determine dose-response characteristics of the PB 
in prostate cancer patients treated using IGRT with standard 
and reduced margins.  
 
Material and Methods: Men with previously untreated 
localised prostate cancer were randomised within the 
multicentre CHHiP (Conventional or Hypofractionated High 
dose Intensity Modulated Radiotherapy for Prostate Cancer) 
IGRT sub-study (CRUK/06/16). Men were randomised to 
receive 2Gy or 3Gy per fraction, delivered either with or 
without daily online image-guidance, with standard or 
reduced CTV-PTV margins. Short course hormone therapy 
(HT) was allowed and details were recorded.  
EP was assessed at baseline, pre-RT and at 6 monthly 
intervals to 2 years, then annually to 5 years post-RT. EP was 
physician graded as normal erection (G0), decreased (G1), 
absent (G2) and unknown. Analysis included the subset of 
men treated with IGRT within the sub-study with an EP 
assessment at 2 years.  
Planning CT scans and reference dose distributions were 
imported into analysis software (Vodca, MSS GmbH). The PB 
was retrospectively contoured using established anatomical 
boundaries (1) and published guidelines (2,3) by one 
clinician. In-house software was used to convert the 
hypofractionated plans into equivalent dose in 2Gy per 
fraction using the Withers formula (α/β = 3Gy). PB dose-
volume (DVH) parameters were evaluated against EP at 2 
years using atlases of complication incidence (ACI) (Matlab, 
Mathworks, Natick, MA) for G2 EP. Dose-volume constraints 
were derived using ROC analysis (Youden index) and assessed 
against the no information rate. 
 
Results: Between June 2010 and June 2011, 293 men entered 
the study. Complete dose-EP data sets were available for 129 
men treated with IGRT. 14/129 men had G2 EP at baseline 
and were excluded. At 2 years, 27/52 (52%) men treated with 
standard margins (IGRTS) and 25/63 (40%) men treated with 
reduced margins (IGRTR) had G2 EP. HT characteristics 
between the two groups were similar. The PB volume was 
7.1(±2.8)cm³ in IGRTS group and 6.5(±2.5)cm³ in IGRTR 
group. The reduced margins resulted in a reduction in dose to 
the PB and statistically significant dose-volume constraints 
for G2 EP were derived for 45, 50, 55, 60 and 65Gy (Table 1). 
The ACI is presented in Figure 1 and demonstrates a dose-
volume response. 
 
 
 
 
